Get started
Author

Sonia Boyer‐Suavet

Observed names: Boyer, Sonia, Boyer-Suavet, Sonia, S Boyer-Suavet (13346457), S. Boyer, S. Boyer-Suavet, Sonia Boyer, Sonia Boyer-Suavet, Sonia Boyet-Suavet
Observed institutions: University of North Carolina at Chapel Hill, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Hôpital Pasteur, Université Nice Sophia Antipolis, Unité de Recherche Clinique Côte d'Azur
OpenAlex ID: A5060086678
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
2019 · Aliza Thompson, Kevin Carroll, et al. · Clinical Journal of the American Society of Nephrology · 333
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
2020 · Eric Rondeau, Marie Scully, et al. · Kidney International · 231
PDF
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
2020 · Sonia Boyer-Suavet, Marine Andreani, et al. · Frontiers in Immunology · 130
PDF
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
2022 · Maxime Teisseyre, Marion Cremoni, et al. · Frontiers in Immunology · 96
PDF
Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses
2020 · Marion Cremoni, Vesna Brglez, et al. · Frontiers in Immunology · 67
PDF
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
2021 · Thomas Barbour, Marie Scully, et al. · Kidney International Reports · 65
PDF
Rituximab bioavailability in primary membranous nephropathy
2019 · Sonia Boyer-Suavet, Marine Andreani, et al. · Nephrology Dialysis Transplantation · 61
Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
2019 · Eveline Y. Wu, Elizabeth A. McInnis, et al. · Arthritis & Rheumatology · 59
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
2021 · Maxime Teisseyre, Marion Cremoni, et al. · Frontiers in Immunology · 56
PDF
Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients
2021 · Caroline Ruetsch, Vesna Brglez, et al. · Frontiers in Medicine · 56
PDF
Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study
2017 · Julien Demiselle, Johann Auchabie, et al. · Annals of Intensive Care · 44
PDF
Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation
2019 · Maël Lateb, Hajar Ouahmi, et al. · Journal of Immunology Research · 42
PDF
Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
2021 · Maxime Teisseyre, Sonia Boyer-Suavet, et al. · Kidney International Reports · 39
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
2023 · Maxime Teisseyre, Vesna Brglez, et al. · Clinical Journal of the American Society of Nephrology · 27
Complement Pathways in Membranous Nephropathy: Complex and Multifactorial
2020 · Vesna Brglez, Sonia Boyer-Suavet, et al. · Kidney International Reports · 27
PDF
Proteinuria as a Biomarker for COVID-19 Severity
2021 · Hajar Ouahmi, Johan Courjon, et al. · Frontiers in Physiology · 25
PDF
Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France
2022 · Jean-François Verdier, Sonia Boyer, et al. · BMC Nephrology · 15
PDF
Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial
2020 · Vesna Brglez, Sonia Boyer-Suavet, et al. · Frontiers in Medicine · 15
PDF
Functional immune assay using interferon-gamma could predict infectious events in end-stage kidney disease
2019 · S. Boyer-Suavet, M. Cremoni, et al. · Clinica Chimica Acta · 14
PDF
Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study
2021 · Marion Cremoni, Caroline Ruetsch, et al. · Frontiers in Medicine · 10
PDF
Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296
2020 · Eric Rondeau, Marie Scully, et al. · Kidney International · 4
Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor–associated membranous nephropathy
2025 · Maxime Teisseyre, Alexandre Destere, et al. · Clinical Kidney Journal · 3
PDF
Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296
2021 · Eric Rondeau, Marie Scully, et al. · Kidney International · 3
Corrigendum to “Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy” [Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]
2024 · Maxime Teisseyre, Sonia Boyer-Suavet, et al. · Kidney International Reports · 2
Kidney biopsy during pregnancy: indications, complications, results, and therapeutic impact
2026 · Camille Imbert, Gaëlle Guettrot-Imbert, et al. · Nephrology Dialysis Transplantation · 1
Works count: 50
Citation count: 1,427
H-index: 16
I10-index: 20
Year
Topic
Type